Stay updated with breaking news from Aad. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Siperstein highlighted some more major takeaways from her conference presentation, including facts about how to determine which patients are good candidates for microneedling.
In recently-presented data, ivarmacitinib was found to have decreased severity of moderate-to-severe eczema compared to placebo.
As the pandemic passes its third year, one dermatologist foresees their field's own pursuit of specialty-specific vaccination guidelines.
In another interview segment, Cohen described several other major takeaways from his conference presentation on psoriasis, comorbidities, and therapies.
New late-breaking data showed that oral roflumilast treatment was both safe and efficacious against psoriasis, making it a potentially less expensive and convenient treatment alternative.